- Home
- FURY vs COEP Comparison
FURY vs COEP Comparison
Compare FURY & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FURY | COEP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 6 |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 91.2M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | FURY | COEP |
|---|---|---|
| Price | $0.57 | $16.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.70 | N/A |
| AVG Volume (30 Days) | ★ 338.5K | 92.3K |
| Earning Date | 08-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $6.80 |
| 52 Week High | $1.02 | $21.41 |
Technical Indicators
Market Signals| Indicator | FURY | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 72.18 |
| Support Level | $0.51 | $13.77 |
| Resistance Level | $0.63 | $19.19 |
| Average True Range (ATR) | 0.03 | 1.15 |
| MACD | -0.00 | 0.47 |
| Stochastic Oscillator | 1.59 | 87.62 |
Price Performance
Historical ComparisonAbout FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.